Want to see PYXS full AI Analyst Report?
Top Page
Pyxis Oncology
(NASDAQ:PYXS)
Select Model
Select Model
Rating:54Neutral
Price Target:
$3.00
▲(80.72% Upside)
Action:Reiterated
Date:07/08/26
The score is held back primarily by weak financial performance—large ongoing losses, heavy cash burn, and a shrinking equity base—despite moderate leverage. Offsetting this, technical momentum is strong with price above key moving averages and a positive MACD, and the recent private placement meaningfully strengthens near-term liquidity/runway. Valuation remains constrained by negative earnings and no dividend yield.
Positive Factors
Private placement extends runway
The ~$50M private placement meaningfully extends near-term liquidity into Q2 2027, allowing continued execution of clinical development and data readouts without immediate fundraising. This reduces short-term existential risk and gives management time to advance MICVO trials and generate value-driving clinical milestones.
Negative Factors
Persistent heavy cash burn
Sustained negative operating and free cash flow (~-$67M TTM) shows structural cash consumption from R&D and operations. Absent successful partnerships, product approvals, or recurring revenue, the company will remain reliant on capital markets to fund operations, increasing dilution risk and creating ongoing financing execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Private placement extends runway
The ~$50M private placement meaningfully extends near-term liquidity into Q2 2027, allowing continued execution of clinical development and data readouts without immediate fundraising. This reduces short-term existential risk and gives management time to advance MICVO trials and generate value-driving clinical milestones.
Read all positive factors
Pyxis Oncology Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how the company’s sales are split across business lines and markets—such as product sales, licensing and milestone payments, services or partnerships, and geographic regions—highlighting which areas drive growth and cash flow. A heavy concentration in one product or partner raises revenue risk and volatility, while diversified or recurring streams point to more stable, scalable upside. For smaller or clinical-stage biotech firms, low commercial revenue and reliance on milestone/license payments warn that future earnings depend on clinical progress and deal-making.
Shows how the company’s sales are split across business lines and markets—such as product sales, licensing and milestone payments, services or partnerships, and geographic regions—highlighting which areas drive growth and cash flow. A heavy concentration in one product or partner raises revenue risk and volatility, while diversified or recurring streams point to more stable, scalable upside. For smaller or clinical-stage biotech firms, low commercial revenue and reliance on milestone/license payments warn that future earnings depend on clinical progress and deal-making.
Data provided by:
The Fly
The FlyPyxis Oncology (PYXS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$169.16M
Dividend YieldN/A
Average Volume (3M)757.02K
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue GrowthN/A
EPS Growth17.43%
CountryUS
Employees56
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.31
Shares Outstanding63,355,480
10 Day Avg. Volume789,983
30 Day Avg. Volume757,017
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)1.34
Price to Sales (P/S)5.16
P/FCF Ratio-1.13
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue9.48
Enterprise Value/Gross Profit9.50
Enterprise Value/Ebitda-1.73
Forecast
1Y Price Target
$6.50Price Target Upside291.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.21
Revenue Forecast (FY)$58.33K
Pyxis Oncology Business Overview & Revenue Model
Company Description
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobu...
How the Company Makes Money
null...
Pyxis Oncology Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
48
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.86M | 13.86M | 16.15M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 13.83M | 11.47M | 15.67M | 0.00 | 0.00 | 0.00 |
| EBITDA | -75.93M | -73.72M | -65.51M | -71.86M | -120.01M | -75.33M |
| Net Income | -81.73M | -79.62M | -77.33M | -73.79M | -120.72M | -75.97M |
Balance Sheet | ||||||
| Total Assets | 64.30M | 91.52M | 157.18M | 173.73M | 211.38M | 280.02M |
| Cash, Cash Equivalents and Short-Term Investments | 42.49M | 66.86M | 126.93M | 119.30M | 179.29M | 274.74M |
| Total Debt | 18.26M | 18.67M | 20.20M | 21.33M | 18.92M | 165.00K |
| Total Liabilities | 33.03M | 38.11M | 36.43M | 48.02M | 50.55M | 18.71M |
| Stockholders Equity | 31.27M | 53.41M | 120.75M | 125.70M | 160.82M | 261.31M |
Cash Flow | ||||||
| Free Cash Flow | -66.98M | -63.51M | -57.91M | -77.44M | -95.73M | -35.87M |
| Operating Cash Flow | -66.97M | -63.50M | -57.67M | -70.71M | -89.33M | -35.33M |
| Investing Cash Flow | 59.41M | 58.86M | 8.15M | -104.85M | -6.40M | -590.00K |
| Financing Cash Flow | 569.00K | 594.00K | 59.33M | 5.93M | 183.00K | 304.04M |
Pyxis Oncology Technical Analysis
Positive
1.66
Price Trends
2.12
Positive
1.83
Positive
2.34
Positive
Market Momentum
0.23
Negative
57.78
Neutral
36.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PYXS, the sentiment is Positive. The current price of 1.66 is below the 20-day moving average (MA) of 2.36, below the 50-day MA of 2.12, and below the 200-day MA of 2.34, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 57.78 is Neutral, neither overbought nor oversold. The STOCH value of 36.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PYXS.
Pyxis Oncology Risk Analysis
Pyxis Oncology disclosed 77 risk factors in its most recent earnings report. Pyxis Oncology reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pyxis Oncology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $578.49M | -14.06 | -147.78% | ― | ― | -16.88% | |
54 Neutral | $169.16M | -1.99 | -135.60% | ― | ― | 17.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $212.49M | -2.16 | -30.90% | ― | ― | 10.70% | |
44 Neutral | $95.44M | -1.48 | -196.72% | ― | ― | 74.83% | |
42 Neutral | $81.66M | ― | -2748.16% | ― | ― | 43.68% |
* Healthcare Sector Average
PYXS
Pyxis Oncology
2.67
1.48
124.37%
NKTX
Nkarta
2.97
1.08
57.14%
GLSI
Greenwich LifeSciences
19.80
8.99
83.16%
ELTX
Elicio Therapeutics
3.48
-5.52
-61.33%
BMEA
Biomea Fusion
1.32
-0.62
-31.96%
NVCT
Nuvectis Pharma
18.35
10.13
123.24%
Pyxis Oncology Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Pyxis Oncology Raises Capital Through Private Placement Financing
Positive
Jul 2, 2026
Pyxis Oncology entered into definitive securities purchase agreements on June 30, 2026 for a private placement of 19,600,153 shares of common stock at $2.551 per share and accompanying warrants to buy an equal number of shares at $3.289, led by BV...
Executive/Board ChangesShareholder Meetings
Pyxis Oncology Stockholders Approve Directors and Auditor Slate
Positive
Jun 15, 2026
On June 15, 2026, Pyxis Oncology, Inc. held its Annual Meeting of Stockholders virtually, with a quorum of 47,302,035 shares represented out of 62,855,464 eligible shares as of the April 20, 2026 record date. Stockholders elected Thomas Civik, Fre...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.